Skip to main content
. Author manuscript; available in PMC: 2022 Nov 28.
Published in final edited form as: Growth Horm IGF Res. 2018 Aug 29;42-43:52–57. doi: 10.1016/j.ghir.2018.08.003

Table 2.

Characteristics of mice with postnatal Ghr gene disruption using the Cre-lox system.

Characteristic iC-GHRKO aGHRKO a6mGHRKD
Disrupted gene GHR (exon 4) GHR (exon 4) GHR (exon 4)
CRE promoter/locus MerCreMer ROSA26 ROSA26
Tissue specificity Adult cardiac myocytes Global Global
Age of disruption 4 weeks 6 weeks 6 months
TAM dose 0.08 mg/ g body weight between 0.25 to 0.32 mg/ g body weight (5 mg total) 0.32 mg/ g body weight
TAM dose regimen 2 IP injections (once daily injection) 5 IP injections (once daily injection for 5 consecutive days) 5 IP injections (one daily injection for 5 consecutive days)